Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $21.00 Average PT from Brokerages

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have received a consensus rating of “Buy” from the six analysts that are covering the company, MarketBeat reports. Six investment analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $21.00.

Separately, HC Wainwright began coverage on shares of Artiva Biotherapeutics in a research note on Monday, December 30th. They set a “buy” rating and a $20.00 price target for the company.

Artiva Biotherapeutics Price Performance

ARTV stock opened at $5.87 on Friday. The business has a 50 day simple moving average of $5.50 and a 200-day simple moving average of $9.68. Artiva Biotherapeutics has a twelve month low of $3.37 and a twelve month high of $17.31.

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ARTV. Charles Schwab Investment Management Inc. acquired a new stake in shares of Artiva Biotherapeutics in the 3rd quarter worth $623,000. BNP Paribas Financial Markets acquired a new stake in Artiva Biotherapeutics in the third quarter valued at about $42,000. MetLife Investment Management LLC acquired a new stake in Artiva Biotherapeutics in the third quarter valued at about $135,000. Acuta Capital Partners LLC acquired a new position in Artiva Biotherapeutics during the 3rd quarter worth approximately $680,000. Finally, RTW Investments LP acquired a new position in Artiva Biotherapeutics during the 3rd quarter worth approximately $2,300,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.